Zerbaxa (Ceftolozane/Tazobactam) Patent Expiration, LOE Window & CMS Spending
Zerbaxa (Ceftolozane/Tazobactam) by Merck & Co.: FDA Orange Book core substance LOE 2034-11-28 (last listed 2036-02-14), 0 AB generics, $24.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N206829 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-11-28 |
| Last Listed Patent or Exclusivity Date | 2036-02-14 |
| Orange Book Patents (*PED Extensions) | 24 patents (12 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $24.1M |
| 2024 Medicare Part D Spend | $18.0M |
| 2024 Medicaid Spend | $6.1M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 32.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.